EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

MASLD: Spatial Mechanisms and New Therapeutics

Christian Stoess iD, Janset Onyuru iD, Yanzhu Hu iD, Yuan Jiang, Zhengyi Xin, Aryan Panchal, Phillipp Hartmann

Biomolecules · 03.08.2026 · 16 (8) · 1129

DOI: 10.3390/biom16081129 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 03.08.2026. Verfasst von Christian Stoess und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery School of Medicine and Health, Technical University of Munich, TUM University Hospital, 81675 Munich, Germany. Hauptthemen laut MEDLINE: Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIDDK NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver injury ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), a progressive inflammatory state associated with hepatocyte injury, fibrosis, cirrhosis, and hepatocellular carcinoma. Increasing evidence suggests that progression to MASH is not spatially uniform across the liver. Instead, it reflects region-specific metabolic stress, inflammatory signaling, and fibrogenic remodeling along the porto-central axis of the hepatic lobule. Recent advances in spatial transcriptomics, lipidomics, proteomics, and multiplex imaging have provided new insight into how hepatocytes, immune cells, endothelial cells, and hepatic stellate cells interact within distinct hepatic microenvironments during disease progression. In this review, we discuss emerging concepts linking hepatic zonation to steatosis, inflammation, fibrosis, and extracellular matrix remodeling in MASLD and MASH. We highlight how disruption of normal lobular organization contributes to a progressive loss of metabolic compartmentalization and to the amplification of inflammatory and fibrogenic signaling. We additionally examine how spatial disease programs differ between adult and pediatric MASLD, particularly given the periportal-predominant injury patterns frequently observed in children and the current lack of pediatric-focused mechanistic studies. Finally, we discuss recently approved therapies and emerging therapeutic strategies within the context of hepatic microenvironment remodeling and disease heterogeneity. Collectively, these findings support a framework in which MASLD and MASH are spatially organized diseases driven by dynamic multicellular interactions, emphasizing the importance of incorporating zonation and tissue context into future mechanistic studies and therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverNon-alcoholic Fatty Liver DiseaseHumansAnimalsLiverHepatic Stellate CellsHepatocytesLiver Cirrhosis

Stichwörter der Autor:innen

MASHMASLDhepatic fibrosishepatic stellate cellsliver zonationpediatric MASLDsteatosis

Autor:innen und Institutionen

  • Department of Surgery School of Medicine and Health, Technical University of Munich, TUM University Hospital, 81675 Munich, Germany.
  • Department of Pediatrics, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093-0984, USA.
  • Division of Gastroenterology, Hepatology & Nutrition, Rady Children's Hospital San Diego, San Diego, CA 92123, USA.

ORCID-Profile: Christian Stoess, Janset Onyuru, Yanzhu Hu

Förderung

  • NIH HHS
  • NIDDK NIH HHS
  • NICHD NIH HHS
  • NCATS NIH HHS
  • Altman Clinical and Translational Research Institute (ACTRI)
  • San Diego Digestive Diseases Research Center
  • American Association for the Study of Liver Diseases
  • National Institutes of Health

Zitieren

APA

Stoess, C., Onyuru, J., Hu, Y., Jiang, Y., Xin, Z., Panchal, A., & Hartmann, P. (2026). MASLD: Spatial Mechanisms and New Therapeutics. Biomolecules, 16(8), 1129. https://doi.org/10.3390/biom16081129

Vancouver

Stoess C, Onyuru J, Hu Y, Jiang Y, Xin Z, Panchal A, et al. MASLD: Spatial Mechanisms and New Therapeutics. Biomolecules. 2026;16(8):1129. doi:10.3390/biom16081129

BibTeX
@article{Stoess2026,
  author = {Stoess, Christian and Onyuru, Janset and Hu, Yanzhu and Jiang, Yuan and Xin, Zhengyi and Panchal, Aryan and Hartmann, Phillipp},
  title = {MASLD: Spatial Mechanisms and New Therapeutics},
  journal = {Biomolecules},
  year = {2026},
  volume = {16},
  number = {8},
  pages = {1129},
  doi = {10.3390/biom16081129}
}
Kostenlos starten →